Latest news with #INR100
Economic Times
5 days ago
- Science
- Economic Times
Cosmic fortress
Why do we exist at all? Why does life flourish on this tiny blue planet suspended in vastness of space? According to a video by the science channel Cosmoknowledge, our existence is not just a random miracle - it is protected and sustained by a remarkable set of cosmic forces quietly working in video says that the first of these is the Moon. It orchestrates the tides, influencing life in our oceans. And it silently takes the blow for us, bearing the brunt of countless asteroid strikes that might otherwise have threatened life here. Further out in the Solar System sits Jupiter, our planetary bodyguard. Massive and majestic, Jupiter's powerful gravity acts as a shield, drawing in or deflecting space debris and rogue asteroids. Without it, Earth could face up to 10,000 times more collisions - any one of which might wipe out life in a heartbeat. Then there is the Sun, the life-giver. Beyond its warmth and light, it generates the heliosphere - a vast, invisible bubble that extends well past Pluto. This bubble deflects deadly cosmic radiation, protecting not just Earth but the entire Solar System. We are wrapped in its embrace, sheltered from the galaxy's harshest still, Earth itself is doing its part. Our magnetic field, always in motion, shields us from solar radiation that could strip away the atmosphere. The ozone layer, too, guards us against ultraviolet of these layers - lunar, planetary, solar, magnetic and atmospheric - functions like a rung in a cosmic ladder, holding life aloft. If any one of them were missing or failed in their purpose, we might not be here to contemplate their presence. The ancient seers taught us to look not just outward but inward - to see the universe as not separate from us but intimately woven into our very existence. We are not alone; we are part of a delicate, celestial balance - living in a fortress of light, motion and grace. (Disclaimer: The opinions expressed in this column are that of the writer. The facts and opinions expressed here do not reflect the views of Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Worrying cracks hiding behind MG Motor's own 'house of Windsor' Is India ready to hit the aspirational 8% growth mark? INR1,300 crore loans for INR100? Stamp duty notice to ArcelorMittal, banks. Why failed small businessmen die by suicide when those behind big blow-ups bounce back? Stock Radar: Falling trendline breakout on daily and weekly charts likely to push stock to record highs; check target & stop loss Handle volatility in conventional & unconventional ways: Capital gains & dividend yield. 6 stocks with dividend yield of 4-8%; return of over 22% Keys to wealth creation: Strong balance sheet & patience. 5 large-cap stocks from different sectors with upside potential of up to 38% Defence stocks: Black & white, and many shades of grey. 10 stocks with an upside potential of up to 30%
Time of India
13-06-2025
- Business
- Time of India
INR1,300 crore loans for INR100? Stamp duty notice to ArcelorMittal, banks.
INR1,300 crore loans for INR100? Stamp duty notice to ArcelorMittal, banks. Getty Images Synopsis ArcelorMittal India has been called for enquiry this month over allegations of stamp duty irregularities. Creditors of KSS Petron, a group company, have alleged irregularities in stamp duty payment in assignment of loans in the run up to its acquisition of Essar Steel under the IBC. By N SUNDARESHA SUBRAMANIAN 4 Mins Read, Jun 13, 2025, 05:55 PM IST SHARE THIS NEWS Close Font Size Abc Small Small Abc Normal Normal Abc Large Close A stamp duty dispute has erupted around a 2018 financial transaction involving global steel giant ArcelorMittal and a group of banks. The Collector of Stamps of Mumbai under Maharashtra government has issued a notice for enquiry over alleged irregularities in payment of stamp duty on a loan assignment transaction dating back to 2018. In October 2018, a group of lenders of KSS Petron (KSSPL) led by the State bank of India (SBI) had assigned dues
Yahoo
30-05-2025
- Business
- Yahoo
Alkem Laboratories Ltd (BOM:539523) Q4 2025 Earnings Call Highlights: Strong Domestic Growth ...
Total Revenue from Operations (FY25): INR 129,645 million, a Y-o-Y growth of 2.3%. Q4 Revenue from Operations: INR 31,438 million, with growth of 7.1%. India Sales (Q4): INR 2,155 million, Y-o-Y growth of 8.1%. International Business Sales (Q4): INR 9,747 million, Y-o-Y growth of 7.2%. Net Profit (FY25): INR 21,655 million, Y-o-Y growth of 20.6%. Net Profit (Q4): INR 3,059 million, growth of 4.2%. EBITDA (FY25): INR 25,122 million, Y-o-Y increase of 11.9%. EBITDA Margin (FY25): Expanded from 17.7% in FY24 to 19.4%. R&D Expenses (FY25): INR 5 million, 4.3% of total revenue from operations. Free Expenses (Q4): INR 1,585 million, close to 5% of total revenue. Volume Growth (FY25): 2.1% versus IPM's volume growth of 1.2%. Cadence (End of March 31, 2025): INR 46.2 billion. Warning! GuruFocus has detected 3 Warning Sign with NDSN. Release Date: May 29, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Alkem Laboratories Ltd (BOM:539523) reported a healthy growth in its India business during Q4 FY25, with an 8.1% year-over-year increase in domestic sales. The company achieved an EBITDA margin expansion from 17.7% in FY24 to 19.4% in FY25, indicating improved profitability. Alkem Laboratories Ltd (BOM:539523) outperformed the Indian Pharmaceutical Market (IPM) in volume growth by 90 basis points, with a 2.1% increase compared to IPM's 1.2%. The company is seeing good traction in its international business, excluding the Americas, with several key markets contributing significantly to growth. Alkem Laboratories Ltd (BOM:539523) is making strategic investments in R&D and expanding its biosimilar plant, which is expected to become operational by Q2 FY26, potentially driving future revenue growth. The company faced challenges in the injectable segment, impacting overall performance in certain therapies. Gross margins for Q4 FY25 were lower compared to the previous year due to reduced production and higher expiry in some markets. Alkem Laboratories Ltd (BOM:539523) experienced a mid-single-digit growth in its trade generic business, which has become highly competitive. The US business is expected to see only mid-single-digit growth due to ongoing price erosion and market dynamics. The company anticipates operating losses of INR100 to INR125 crores from its new CDMO and Medtech businesses in FY26, which could impact overall profitability. Q: In India, some major segments like anti-infectives and cardiac showed growth lower than IPM growth. Can you elaborate on this and the outlook for India business growth next year? A: Dr. Vikas Gupta, CEO: Despite some challenges in Q4, our annual performance in key therapies like GI, antidiabetic, and neuro has outperformed the market. We faced challenges in the injectable segment, but our oral solids and liquids have shown strong growth. We expect continued strong performance in our India business, with an 8.1% growth in Q4, and are optimistic about future growth. Q: How should we look at margins for FY26? A: Dr. Vikas Gupta, CEO: We expect EBITDA margins to remain stable at around 19.5% for FY26. While we will gain operating leverage from growth, we are also investing in R&D and market expansions, which will keep margins stable. Q: Can you update us on the biosimilar plant investment and its timeline? A: Dr. Vikas Gupta, CEO: The biosimilar project is on track and expected to be operational by Q2 FY26. We have invested around INR500 crores, and the total CapEx will be about INR550 crores. We anticipate revenue generation within this year. Q: What is the outlook for the US business in terms of growth and product launches? A: Dr. Vikas Gupta, CEO: We expect mid-single-digit growth in the US business for FY26. We plan to launch five to six new products, although no major launches are expected. The market remains competitive with ongoing price erosion, but we are optimistic about growth opportunities. Q: What is the guidance for R&D expenditure for FY26? A: Dr. Vikas Gupta, CEO: We expect R&D expenses to be around 5% of total revenue. This includes filings in non-US markets and the US, with plans to file eight to nine products. The focus will be on complex oral solids and injectables. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Economic Times
14-05-2025
- Automotive
- Economic Times
Tata's EV business loses market share but drives INR100 crore profit in FY25
In a paradox that few would have predicted, Tata Passenger Electric Mobility (TPEM) has turned Ebitda (earnings before interest, taxes, depreciation and amortisation) positive for the first time in FY25 — even as its stranglehold over India's electric vehicle (EV) market weakened significantly. The company reported a profit before tax (PBT) and exceptional items of INR100 crore, reversing a loss of INR400 crore in FY24. The Ebitda turnaround was
Time of India
14-05-2025
- Automotive
- Time of India
Tata's EV business loses market share but drives INR100 crore profit in FY25
In a paradox that few would have predicted, Tata Passenger Electric Mobility (TPEM) has turned Ebitda (earnings before interest, taxes, depreciation and amortisation) positive for the first time in FY25 — even as its stranglehold over India's electric vehicle (EV) market weakened significantly. The company reported a profit before tax (PBT) and exceptional items of INR100 crore, reversing a loss of INR400 crore in FY24. The Ebitda turnaround was
